Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

TC BioPharm Initiates Phase I Trial of Allogeneic Gamma Delta T Cell Therapy in Acute Myeloid Leukemia Patients

TC BioPharm (TCB), a developer of allogeneic CAR-T immuno-oncology products, and leaders in Gamma Delta T (GDT) cell therapies, today announced it has initiated a Phase I clinical study of TCB002, an allogeneic cell therapy consisting of activated and expanded gamma delta T cells. The trial, for treatment of patients suffering from Acute Myeloid Leukemia (AML), is being conducted at the Institute of Hematology and Blood Transfusion (ÚHKT) in Prague, Czech Republic. Patient recruitment commenced January 2019 following regulatory approval late 2018. Dose escalation is in progress, with completion of treatment imminent for the first patient cohort. The clinical trial is registered with identifier NCT03790072.

Developed by TC BioPharm, TCB002 comprises GDT cells sourced from healthy donors, expanded and activated in large numbers before being purified and formulated for infusion into patients. The donors are selected based on criteria designed to ensure that the cells are potent killers of cancer cells, and can be a more effective and consistent treatment compared to the patient's own cells. GDT cells are a subset of lymphocytes which have both innate and adaptive immune properties and represent an emerging therapeutic option for cancer and other diseases. Use of allogeneic GDT cells from healthy donor cell banks paves the way for development of superior drug products through screening and selection of the highest quality starting material, facilitating preparation of consistent batches capable of treating many patients.

The study in Prague is designed to provide safety data on allogeneic use of GDTs prior to subsequent use of CAR-modified variants later in the year. GDTs are an obvious vehicle for allogeneic cell therapies as they do not elicit ?graft versus host' rejection. TCB is developing its proprietary GDT CAR-T (Chimeric Antigen Receptor T Cell) platform in a stepwise manner, evolving the clinical development program from autologous to allogeneic to CAR-modified products.

The first human trial of TCB002 is an ICH GCP compliant, open-label single arm study expected to enroll 9 patients, with three escalating doses of the drug product. Cancer patients in the study are suffering from relapsed or refractory AML and are ineligible or non-consenting to a stem cell transplant. The product is manufactured at TCB's GMP-compliant manufacturing site in the UK using cells sourced from healthy allogeneic donors. The development of this allogeneic product has been supported by a ?4m grant from the European Union's Horizon 2020 research and innovation program.

Angela Scott, Chief Operating Officer, TC BioPharm, said: "Treatment of the first patients with TCB002 represents the culmination of a concerted collective effort from our in-house product development, quality, manufacturing, regulatory and clinical teams, as well as the expert physicians at ÚHKT. We are now focused on successful completion of this trial and the progression of our CAR-T products to treat further patient groups with unmet clinical needs, as part of our strategic plan of delivering allogeneic CAR-T medicines as mainstream cancer therapies."

Prof. Petr Cetkovský, Director, ÚHKT, added: "Collaborating with TC BioPharm on clinical evaluation of Advanced Therapy Medicinal Products allows us to offer experimental options to patients with acute clinical need, and builds upon our position of expertise with pioneers of cellular immuno-oncology products."

This project has received funding from the European Union's Horizon 2020 Research and Innovation program.

These press releases may also interest you

at 04:00
Natalia Kuznetsova, a graduate of a NUST MISIS master's program "Technologies and Materials of Digital Fabrication", has developed a new biodegradable composite material with nettle fiber as a filler. Chemelot Campus (Netherlands), one of the largest...

at 03:00
Online "trolls" - the human kind that is, not the "bots" run by an algorithm rather than a real person - get a thrill from stirring up controversy and conflict, offending people in the most distasteful manner possible, and making light of sobering...

at 00:00
The NAPCP, a professional association that has served the Commercial Card and Payments industry since 1999, has announced the release of its 2020 Commercial Card and Payment Conference marketing opportunities. The NAPCP's community of almost 20,000...

23 aoû 2019
NuTech National, is a 38-year national security alarm technology company based in Maitland, Florida with government clearances, securing government and military contractors (Lockheed Martin, Embraer, Brinks, Dunbar). NuTech's second division includes...

23 aoû 2019
Lyons Companies ("Lyons") takes the security and privacy of all information that it holds very seriously. While there is currently no evidence that there has been any actual or attempted misuse of information, Lyons is providing notice after an...

23 aoû 2019
General Dynamics NASSCO, a subsidiary of General Dynamics , was awarded a contract by the U.S. Navy worth up to $1.6 billion for the construction of the sixth and seventh ships of the Expeditionary Sea Base (ESB) program, as well as an option for ESB...

News published on 24 april 2019 at 04:40 and distributed by: